PLA2G7 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= PLA2G7 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: PLA2G7
  * **<color #00a2e8>Official Name</color>**: phospholipase A2 group VII
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7941|7941]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q13093|Q13093]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=PLA2G7&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PLA2G7|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/601690|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2009]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|PAF-AH p II|
|Abhydrolase 6|
|Chlorophyllase2|
|Abhydrolase 5|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|plasma lipoprotein particle oxidation|
|1-alkyl-2-acetylglycerophosphocholine esterase activity|
|platelet activating factor metabolic process|
|calcium-independent phospholipase A2 activity|
|hydrolase activity, acting on ester bonds|
|low-density lipoprotein particle remodeling|
|low-density lipoprotein particle|
|positive regulation of monocyte chemotaxis|
|positive regulation of mononuclear cell migration|
|regulation of monocyte chemotaxis|
|plasma lipoprotein particle remodeling|
|protein-lipid complex remodeling|
|protein-containing complex remodeling|
|plasma lipoprotein particle organization|
|regulation of mononuclear cell migration|
|protein-lipid complex subunit organization|
|regulation of plasma lipoprotein particle levels|
|lipid oxidation|
|positive regulation of leukocyte chemotaxis|
|phospholipid binding|
|regulation of leukocyte chemotaxis|
|positive regulation of leukocyte migration|
|positive regulation of chemotaxis|
|positive regulation of inflammatory response|
|ammonium ion metabolic process|
|regulation of leukocyte migration|
|lipid modification|
|regulation of chemotaxis|
|lipid catabolic process|
|glycerophospholipid metabolic process|
|regulation of inflammatory response|
|phospholipid metabolic process|
|glycerolipid metabolic process|
|extracellular structure organization|
|positive regulation of defense response|
|drug metabolic process|
|positive regulation of cell migration|
|positive regulation of cell motility|
|positive regulation of cellular component movement|
|positive regulation of locomotion|
|positive regulation of response to external stimulus|
|regulation of defense response|
|regulation of cell migration|
|organophosphate metabolic process|
|regulation of cell motility|
|cellular lipid metabolic process|
|oxidation-reduction process|
|regulation of locomotion|
|regulation of cellular component movement|
|regulation of response to external stimulus|
|positive regulation of immune system process|
|lipid metabolic process|
|regulation of response to stress|
|regulation of immune system process|
|organic substance catabolic process|
|protein-containing complex subunit organization|
|extracellular region|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp513|ONC212 0.15μM R08 exp513]]|1.78|
|[[:results:exp239|PFI-2 4μM R05 exp239]]|1.85|
|[[:results:exp442|Ibrutinib 10μM R08 exp442]]|1.87|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|2.1|
|[[:results:exp144|PFI-3 10μM R03 exp144]]|2.19|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 11367
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 0.06 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='PLA2G7 Expression in NALM6 Cells: 0.06'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>